This informal CPD article ‘Intervention Control: The New Standard for Barrier Systems’, was provided by Pharmalliance Consulting, who offer specialist support to pharmaceutical companies to maintain and increase quality compliance levels.
In the past, barrier technology was often seen as a silver bullet. Install an isolator or RABS, and you were likely ahead of the curve. Today, that mindset won’t pass an audit. Regulators are no longer just asking what barrier systems you use, they’re asking how often you open them, what you do when you do, and what happens next.
Routine vs. Corrective: Know the Difference
One of the clearest inspection trends is the focus on intervention classification. EU Annex 1 and FDA guidance now expect manufacturers to clearly define all interventions, routine (inherent to the process) and non-routine (corrective or unplanned).
These categories aren’t just labels. They inform everything: media fill design, contamination control strategies, gowning requirements, and even environmental monitoring scope. An unplanned RABS door opening? That’s no longer just an inconvenience, it’s a deviation that needs documentation, risk assessment, and possible requalification.
Simulation Isn’t Optional Anymore
Every meaningful intervention must be simulated during aseptic process validation. This includes common actions like glove re-entry, line clearances, equipment adjustments, and even rare but plausible scenarios. Media fills that skip or sanitise away complexity aren’t considered credible anymore.
Annex 1 makes it clear: interventions should be based on real manufacturing data, not assumptions. That means looking at your line stop records, downtime logs, and EM trends to identify where risk really lies.
The Focus Has Shifted from Presence to Practice
In inspections, regulators often ask how a company uses its barrier, not just if it has one. For RABS, this includes:
- How frequently doors are opened?
- Whether those interventions are logged and justified?
- How operators are trained to disinfect afterward?
- If any routine activity can be automated to reduce frequency?
For isolators, the questions often relate to:
- How glove integrity is maintained?
- What happens when a glove fails mid-campaign?
- How you ensure aseptic connection during material transfer?
Inspectors want to see that these scenarios are not just possible, but planned for, and that your team knows exactly what to do when they occur.
Overlooking Minor Interventions Is a Major Issue
A growing focus during inspections is how sites treat low-risk or “quick” interventions. Things like tightening a bolt inside a RABS or repositioning a stopper bowl might not seem like major events, but they still pose contamination risks. Inspectors have cited sites for repeatedly failing to log these actions or for having no procedure that defines how they should be managed. Even brief glove re-entries into Grade A zones must follow a defined process and be documented.
Operator Fatigue and Repeat Behavior
Some facilities have been asked to explain why the same operators are repeatedly performing high-risk interventions. Inspectors are now reviewing trends across batches and shifts to identify whether poor equipment design or operator workload is driving excessive contact with critical zones. If five different interventions are logged within a single campaign, but all by the same person, that raises concern. Sites should be using this data to assess whether process redesign or staffing changes are needed.
Closing the Loop with CAPA and CCS
When interventions go wrong or are poorly controlled, the investigation must tie back to the contamination control strategy. Inspectors expect a clear link between intervention logs, deviation reports, and updates to the CCS. For example, if a glove breach occurs during aseptic filling, there should be evidence of how that data was reviewed, what training was adjusted, and whether future campaigns were modified. This end-to-end traceability is now considered a baseline expectation.
Conclusion
Barrier systems reduce risk, but they don’t eliminate it. Inspectors now expect full transparency around interventions, from classification through simulation to response. The message is clear: a physical barrier is only one part of the defence. The rest comes from your data, your training, and your willingness to own every detail of your process.
We hope this article was helpful. For more information from Pharmalliance Consulting, please visit their CPD Member Directory page. Alternatively, you can go to CPD Industry Hubs for more articles, courses and events relevant to your Continuing Professional Development requirements.
References
The European Commission, 2022. EU Annex 1, Brussels, Belgium.
U.S. Food and Drug Administration, 2004. Part 210 – Current Good Manufacturing Practice in Manufacturing, Processing, Packaging, or Holding of Drugs, United States of America.
U.S. Food and Drug Administration, 2004. Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals, United States of America.
International Council for Harmonisation, 2023. ICH ǪS(R1) – Ǫuality Risk Management, Step 5, Switzerland.
International Council for Harmonisation, 2008. ICH Ǫ10 – Pharmaceutical Ǫuality System, Switzerland.
International Organization for Standardization, 2021. ISO 13408-c – Aseptic Processing of Health Care Products – Part c: Isolator Systems, Geneva, Switzerland.
